Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IAMA-097
- Development stage
- Discontinued
- Lead developer
- IAMA Therapeutics
- Modality
- Small Molecules
01
Overview
**IAMA-097** is a preclinical-stage small molecule chloride modulator developed by IAMA Therapeutics, an Italian biotechnology company founded in 2021 specializing in novel therapies for neurodevelopmental and neuropsychiatric disorders in children. It selectively inhibits the sodium-potassium-chloride cotransporter NKCC1 to restore physiological chloride gradients and inhibitory GABAergic transmission disrupted in neuronal hyperexcitability states. The candidate targets **secondary and rare syndromic forms of autism** (e.g., autism spectrum disorder subtypes associated with genetic syndromes), as well as potentially other brain disorders characterized by cognitive impairment, positioning it as a differentiated follow-on to lead candidate IAMA-6 in IAMA's CNS pipeline.[1][3][4][7][17]
Beyond the preview
Go deeper on IAMA-097.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IAMA-097.